

C₁
from U.S. provisional application 60/067,175, filed December 1, 1997. Both of these applications are incorporated herein by reference.--

Please ~~delete~~ page 8, lines 10-29, and insert therefor:

C₂
--The term "mesothelin" includes references to a mesothelin protein and fragments thereof which may be present on the surface of mammalian cells of a mammal such as rats, mice, and primates, particularly humans. The preferred nucleic acid and amino acid sequences of mesothelin are as described in PCT published application WO 97/25068, U.S. Application 08/776,271 (now U.S. Patent No. 6,083,502) and U.S. Provisional Application 60/010,166, all incorporated herein by reference. In addition, see, Chang, K. & Pastan, I., *Int. J. Cancer* 57:90 (1994); Chang, K. & Pastan, I., *Proc. Nat'l Acad. Sci. USA* 93:136 (1996); Brinkman U., et al., *Int. J. Cancer* 71:638 (1997); and Chowdhury, P.S., et al., *Mol. Immunol.* 34:9 (1997), each of which is incorporated herein by reference. Mesothelin also refers to mesothelin proteins or peptides which remain intracellular as well as secreted and/or isolated extracellular protein.

As used herein, "antibody" includes reference to an immunoglobulin molecule immunologically reactive with a particular antigen, and includes both polyclonal and monoclonal antibodies. The term also includes genetically engineered forms such as chimeric antibodies (e.g., humanized murine antibodies), heteroconjugate antibodies (e.g., bispecific antibodies), recombinant single chain Fv fragments (scFv), and disulfide stabilized (dsFv) Fv fragments (See, U.S.S.N. 08/077,252, now U.S. Patent No. 5,747,654, incorporated herein by reference). The term "antibody" also includes antigen binding forms of antibodies (e.g., Fab', F(ab')₂, Fab, Fv and IgG. See also, Pierce Catalog and Handbook, 1994-1994 (Pierce Chemical Co., Rockford, IL).--

IN THE CLAIMS

Please ~~cancel~~ claims 1-32 and claims 97-112.

Please ~~add~~ the following new claims 113-165.